🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — July 08, 2026

The IPO pipeline for July 8, 2026, is dominated by three distinct offerings: a traditional SPAC (Catalyst Acquisition Corp.), a distressed biotech follow-on (AEON Biopharma), and a controlled-company resale registration (Evolution Metals & Technologies Corp.). The SPAC market shows continued activity with a $200M blank-check IPO targeting media and gaming, though no target has been identified. AEON Biopharma's offering is highly dilutive (immediate dilution of $0.83 per share) and carries existential risk from a potential NYSE American delisting by August 3, 2026, with milestone warrants that are speculative and time-bound. Evolution Metals' resale filing signals potential overhang from a convertible debenture conversion, with the company's 70.18% controlling shareholder structure limiting governance protections. Across the pipeline, period-over-period comparisons are limited as these are initial filings, but the absence of any revenue or operational history for the SPAC and the negative tangible book value trend for AEON highlight a pipeline skewed toward high-risk, speculative structures. The most critical development is AEON's delisting deadline, which creates a binary catalyst for the stock within the next month.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 08, 2026

The single filing in this stream, from Borealis Foods Inc., presents a high-risk delisting scenario on the Nasdaq Capital Market. The company received a deficiency notice for failing to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million, with a 180-day cure period ending December 29, 2026. Critically, Borealis also fails to meet alternative listing standards based on stockholders' equity or net income, significantly narrowing its path to compliance. The negative sentiment and high materiality score (9/10) underscore the existential threat to the company's public listing, with a delisting of common shares automatically triggering the delisting of its warrants (BRLSW). No period-over-period comparisons, insider activity, or forward-looking guidance were provided in the enriched data, limiting trend analysis but amplifying the binary risk of the situation. The lack of any positive catalysts or capital allocation actions (e.g., buybacks) suggests management is in a reactive, rather than proactive, position.

1 high priority 1 total filings
· daily

US Executive Officer Management Changes SEC — July 08, 2026

Today's digest of 28 filings reveals a significant wave of executive and director changes across diverse sectors, with a notable concentration in life sciences and financial services. The most critical development is the overwhelming shareholder approval of Catalyst Pharmaceuticals' merger with Angelini Pharma, despite a non-binding advisory vote against executive compensation, signaling a potential governance concern. Period-over-period data is limited in these filings, but forward-looking statements and compensation structures indicate a strategic shift towards performance-based incentives, as seen with NioCorp's new annual incentive program. Insider activity is sparse, but the appointment of seasoned executives with strong track records, such as Michael Axelrod at BellRing Brands and Jeremy Bender at Aura Biosciences, suggests a focus on growth and operational excellence. Capital allocation trends are mixed, with Seritage Growth Properties offering a modest CEO retention bonus while 374Water's salary deferral signals cash constraints. Overall, the market is witnessing a consolidation of leadership roles and a push for alignment with shareholder interests through enhanced compensation frameworks.

28 high priority 28 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 08, 2026

The 31 filings reveal a bifurcated corporate landscape: while several companies (AEP Texas, Sterling Infrastructure, Energy Transfer) secure large-scale financing for growth and infrastructure, a significant cluster faces acute distress signals—Nasdaq non-compliance (Borealis Foods, Nocera, Future FinTech), high-cost emergency financing (XCF Global, Newton Golf, Clean Energy Technologies), and failed clinical/SPAC deals (Alector, Aimei Health). Period-over-period data is sparse, but insider activity shows CEO Woodman personally lending $20M to GoPro, a strong vote of confidence. Capital allocation trends include debt refinancings (Civeo, Voyager, CPKC) and bolt-on M&A (Byrna, Tarsus, ReposiTrak). The distressed cohort is concentrated in micro-cap and pre-revenue biotech/tech, while mid-cap energy and infrastructure firms demonstrate financial strength.

31 high priority 31 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 08, 2026

This digest of 28 SEC filings reveals a boardroom landscape characterized by strategic succession planning and targeted appointments, particularly in the industrial and healthcare sectors. A key theme is the appointment of seasoned executives with deep operational and financial expertise, such as at Ultra Clean Holdings and BellRing Brands, signaling a focus on execution and growth. The period-over-period data is limited in these filings, but the forward-looking nature of these appointments, combined with insider activity like the special equity awards at Longeveron, provides actionable intelligence. The most critical development is the overwhelming shareholder approval of Catalyst Pharmaceuticals' merger with Angelini Pharma, a high-materiality event that will result in the resignation of all current directors. While most changes are neutral, the positive sentiment around several appointments and the mixed signals from shareholder votes at Seres Therapeutics and Catalyst highlight areas for investor attention. The overall pattern suggests a market where companies are proactively refreshing leadership to navigate specific strategic phases, from turnarounds to growth acceleration.

28 high priority 28 total filings
· daily

USA Insider Trading Pulse — July 08, 2026

Today's insider trading pulse reveals a clear divergence: a wave of insider selling, particularly from C-suite executives executing Rule 10b5-1 plans, contrasts with selective, high-conviction insider buying by significant shareholders and directors. The most notable bearish signals come from Darden Restaurants (SVP sold $2.05M), Pampa Energy (Director sold $5.32M), and Insmed (CMO sold $824K), while bullish signals are isolated to CION Ares (10% owner bought $10.5M) and Larimar Therapeutics (Director bought $167K). A significant cluster of option awards at Niocorp Developments signals a long-term incentive alignment for its management team. The data shows a prevalence of neutral, routine equity awards and tax-withholding sales, which are non-signals, but the sheer volume of 10b5-1 plan sales from senior officers at multiple companies warrants a cautious stance on those specific equities. The overall market sentiment is mixed, with no single sector dominating the insider activity, but the concentration of selling in consumer discretionary and energy suggests potential headwinds.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 08, 2026

The July 8, 2026, M&A digest reveals a bifurcated market: SPAC activity is surging (5 IPOs/business combinations), but with significant execution risk, as evidenced by high redemption rates (Securitize: 23%), going-concern qualifications (Quantum Leap), and restatements (FutureTech II). The real asset and energy transition themes are prominent, with IQM Quantum Computers and Air Water Ventures closing deals, while traditional energy M&A (Presidio Production) shows strong projected returns (~20% FCF yield). Divestitures are a key capital allocation tool, with CommScope/Vistance Networks ($1.846B) and Azenta ($63M) streamlining operations. However, distress is also present, highlighted by Charles & Colvard's bankruptcy sale for $2.7M and Ashford Hospitality's asset sale to deleverage. Period-over-period data from pro-forma statements reveals that divested assets (e.g., RUCKUS) were disproportionately profitable, raising concerns about the quality of remaining businesses. Insider activity is limited, but the high redemption rates and material weakness disclosures signal management and market skepticism on several SPAC deals. The overall sentiment is mixed, with high-volume, high-valuation deals in quantum and real estate contrasting with distressed exits and accounting failures.

17 high priority 17 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 08, 2026

Overnight SEC filings reveal a mixed landscape with notable insider selling in biotech and tech, while capital raising and regulatory risks dominate headlines. Key period-over-period trends include Butler National Corp's strong 16.9% revenue growth driven by a 32.6% surge in Aerospace Products, contrasted with a 9.3% operating income decline in its Professional Services segment. The most critical developments include a major SPAC merger (Graf Global/Big3) valued at $290M, a high-profile IPO filing from autonomous trucking company Einride AB, and significant regulatory risks at Amphastar Pharmaceuticals (FDA Warning Letter) and Inno Holdings (Nasdaq trading halt). Portfolio-level patterns show a concentration of blank-check companies (Samos Energy, Catalyst Acquisition, Cartesian Growth Corp IV) raising capital, and a wave of insider selling under 10b5-1 plans, particularly in biotech (Neurogene, MeiraGTx) and tech (Airbnb).

34 high priority 16 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 07, 2026

All 6 FDA approvals in this period are biosimilar entries, with zero NMEs or label expansions, indicating a routine regulatory week focused on generic competition rather than innovative catalysts. The dominant theme is the duplicative entry into rivaroxaban (Mankind Pharma and Micro Labs), signaling intensifying generics competition for the anticoagulant market. Zydus Pharms USA Inc received two approvals (metformin hydrochloride and selenious acid), demonstrating steady generic pipeline execution. No bullish or bearish signals were flagged; all approvals are neutral, reflecting mature market entries with limited near-term commercial impact for institutional investors. The lack of NMEs or breakthrough therapies prevents any therapeutic area clustering.

6 total filings
· daily

Big Pharma Approvals — July 07, 2026

This July 7, 2026 digest covers two Novartis approvals classified as 'Other' (FALLBACK type), with no NMEs, biosimilars, or standard label expansions. The dominant signal is a bullish label expansion for RIBOCICLIB SUCCINATE (KISQALI), which strengthens Novartis's oncology franchise despite undisclosed commercial specifics. A neutral biosimilar approval for LETROZOLE adds incremental competition in the aromatase inhibitor space but lacks material near-term impact. The highest-conviction signal is KISQALI's label expansion, which could extend its CDK4/6 inhibitor market position against IBRANCE (Pfizer) and VERZENIO (Eli Lilly). Key risk: the FALLBACK classification suggests these approvals may have faced prior regulatory setbacks or are lower-priority filings, warranting scrutiny on commercial execution.

2 total filings
· daily

New Drug Approvals (Original) — July 07, 2026

This digest covers a batch of six FDA approvals from the period ending July 7, 2026, comprised entirely of generic/biosimilar approvals (0 NMEs, 0 biosimilars as defined by the stream, 0 label expansions). The approvals are dominated by small-molecule generics and follow-on entries including two separate approvals for rivaroxaban (Mankind Pharma and Micro Labs), metformin hydrochloride (Zydus Pharms USA Inc), adapalene (Unique), selenious acid (Zydus Pharms), and everolimus (i3 Pharms). There is no single dominant therapeutic area theme beyond general chronic disease management (anticoagulation, diabetes, oncology). The batch carries no bullish flags for originator stocks, but signals modestly negative competitive pressure on Johnson & Johnson/Bayer (for Xarelto/rivaroxaban) and Novartis (for Afinitor/everolimus) from new generic entrants. Key risk is the high volume of narrow-therapy generic approvals lacking differentiation, offering minimal catalyst value for large-cap pharma holdings.

6 total filings
· daily

HHS & Healthcare Contracts Intelligence — July 07, 2026

This digest covers a single, high-value $144.8 million civilian contract awarded by HHS/ASPR to SAFESOURCE DIRECT LLC, a small business manufacturer, for domestic industrial base expansion of nitrile butadiene rubber (NBR) critical for medical gloves and PPE. The contract is fully civilian (0% defense-related) and carries a bullish signal with a 7/10 strength, reflecting strong execution with $118.9 million already outlayed. The dominant theme is U.S. government investment in pandemic-preparedness supply chain resilience, favoring small domestic manufacturers. Key risk: the contract runs through December 2026, with no follow-on awards yet, creating execution and re-compete uncertainty for SAFESOURCE DIRECT LLC.

1 total filings
· daily

New Federal Contractors — July 07, 2026

This digest covers a single, large civilian contract awarded to SAFESOURCE DIRECT LLC by the Department of Health and Human Services (HHS/ASPR) valued at $144.8 million, representing the entire $144.8 million total obligation across the period. The contract is entirely civilian (0/1 defense-related) and signals a strong government push to onshore critical medical supply chain capacity, specifically for nitrile butadiene rubber (NBR) used in medical gloves. The highest-conviction signal is the bullish award to a small business that won under full and open competition, with $118.9 million already outlayed, indicating robust execution and cash flow. A key risk is the contract's expiration in December 2026, creating a re-compete cliff that could pressure revenue if follow-on awards are not secured.

1 total filings
· daily

Significant Contract Modifications ($10M+) — July 07, 2026

This digest covers a single, large civilian contract modification from HHS/ASPR to SAFESOURCE DIRECT LLC valued at $144.8 million, with no defense-related awards. The dominant theme is domestic industrial base expansion for pandemic preparedness, specifically for NBR (nitrile butadiene rubber) production critical to medical gloves and PPE. The highest-conviction signal is the firm-fixed-price structure and $118.9 million already outlayed, indicating strong cash flow and execution. A key risk is the contract's expiration in December 2026, with no follow-on awards yet visible, creating a potential revenue cliff for this small business.

1 total filings
· daily

Contract Deobligations Alert — July 07, 2026

The digest covers a single $144.8 million civilian contract awarded by HHS/ASPR to SAFESOURCE DIRECT LLC for industrial base expansion of nitrile butadiene rubber (NBR), a critical material for medical gloves and PPE. The contract is firm-fixed-price with $118.9 million already outlayed, indicating strong execution and cash flow. This award underscores the government's commitment to domestic supply chain resilience for pandemic preparedness, a key civilian-sector theme. The highest-conviction signal is bullish, reflecting a small business winning against larger competitors under full competition. A key risk is the contract's expiration in December 2026, with no follow-on awards yet identified.

1 total filings
· daily

Contract Option Exercises — July 07, 2026

This digest covers a single contract option exercise period from July 7, 2026, totaling $144.8 million in obligations, with zero defense-related awards. The dominant theme is civilian agency investment in domestic supply chain resilience, specifically the Department of Health and Human Services (HHS) awarding a $144.8 million firm-fixed-price contract to SAFESOURCE DIRECT LLC for industrial base expansion of nitrile butadiene rubber (NBR), a critical material for medical gloves. The highest-conviction signal is bullish, reflecting strong government commitment to pandemic preparedness and domestic manufacturing, with $118.9 million already outlayed indicating robust execution. A key risk is the contract's expiration in December 2026, creating a re-compete cliff for SAFESOURCE DIRECT LLC, and potential market saturation from competitor capacity expansions.

1 total filings
· daily

All HHS Contracts — July 07, 2026

The single HHS contract analyzed, a $144.8 million firm-fixed-price award to SAFESOURCE DIRECT LLC, underscores a targeted civilian agency push to onshore critical medical supply chain components, specifically nitrile butadiene rubber (NBR) for gloves. With no defense-related contracts in this period, the digest is purely civilian, carrying an average signal strength of 7.0/10. The highest-conviction signal is the contract's strong execution, with $118.9 million already outlayed, indicating robust cash flow and performance. A key risk is the contract's expiration in December 2026, creating a re-compete cliff for SAFESOURCE DIRECT LLC.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — July 07, 2026

This digest covers a single mega contract ($144.8M total obligation) awarded by the Department of Health and Human Services (HHS) to SAFESOURCE DIRECT LLC, a small business manufacturer. The contract is entirely civilian, with zero defense-related awards, reflecting a focused investment in domestic supply chain resilience for pandemic preparedness. The highest-conviction signal is the $118.9M already outlayed against the contract, indicating strong execution and cash flow for SAFESOURCE DIRECT. A key risk is the contract's expiration in December 2026, with no follow-on awards yet visible, creating potential revenue cliff exposure for the company.

1 total filings
· daily

High-Value Federal Grants ($5M+) — July 07, 2026

The digest covers a single, high-value civilian contract totaling $144.8 million from the Department of Health and Human Services (HHS) to SAFESOURCE DIRECT LLC for domestic nitrile butadiene rubber (NBR) production, a critical input for medical gloves. This award is a strong bullish signal for small-cap domestic manufacturing tied to pandemic preparedness, with $118.9 million already outlayed, indicating robust execution and cash flow. The contract is firm-fixed-price, won under full and open competition, suggesting SAFESOURCE DIRECT LLC possesses a competitive edge against larger rivals. Key risks include the contract's expiration in December 2026 and potential market saturation from competitor capacity expansions.

1 total filings
· daily

General Federal Contracts — July 07, 2026

This digest covers a single, large civilian contract from the Department of Health and Human Services (HHS) to SAFESOURCE DIRECT LLC valued at $144.8 million, with zero defense-related awards. The dominant theme is HHS/ASPR's strategic investment in domestic industrial base expansion for pandemic preparedness, specifically for nitrile butadiene rubber (NBR) production. The highest-conviction signal is the strong execution and cash flow demonstrated by $118.9 million already outlayed on a firm-fixed-price contract, indicating high revenue recognition and competitive capability. A key risk is the contract's expiration in December 2026, creating a re-compete event that could disrupt revenue if SAFESOURCE DIRECT LLC fails to secure a follow-on award.

1 total filings